278 related articles for article (PubMed ID: 12948863)
1. Messenger RNA expression profiling of genes involved in epidermal growth factor receptor signalling in human cancer cells treated with scanning array-designed antisense oligonucleotides.
Petch AK; Sohail M; Hughes MD; Benter I; Darling J; Southern EM; Akhtar S
Biochem Pharmacol; 2003 Sep; 66(5):819-30. PubMed ID: 12948863
[TBL] [Abstract][Full Text] [Related]
2. A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides.
Hussain M; Shchepinov M; Sohail M; Benter IF; Hollins AJ; Southern EM; Akhtar S
J Control Release; 2004 Sep; 99(1):139-55. PubMed ID: 15342187
[TBL] [Abstract][Full Text] [Related]
3. Antiproliferative effect of c-myc antisense phosphorothioate oligodeoxynucleotides in malignant glioma cells.
Broaddus WC; Chen ZJ; Prabhu SS; Loudon WG; Gillies GT; Phillips LL; Fillmore H
Neurosurgery; 1997 Oct; 41(4):908-15. PubMed ID: 9316053
[TBL] [Abstract][Full Text] [Related]
4. EGFR antisense oligonucleotides encapsulated with nanoparticles decrease EGFR, MAPK1 and STAT5 expression in a human colon cancer cell line.
Najar AG; Pashaei-Asl R; Omidi Y; Farajnia S; Nourazarian AR
Asian Pac J Cancer Prev; 2013; 14(1):495-8. PubMed ID: 23534780
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.
Leonetti C; D'Agnano I; Lozupone F; Valentini A; Geiser T; Zon G; Calabretta B; Citro G C; Zupi G
J Natl Cancer Inst; 1996 Apr; 88(7):419-29. PubMed ID: 8618233
[TBL] [Abstract][Full Text] [Related]
6. [An EGFR antisense oligodeoxynucleotides and its phosphorothioate analogue inhibit the growth of human hepatocarcinoma BEL-7404 cells].
Lin JQ; Xu ZS; Zhang HY; Yang ZW; Xu YH
Shi Yan Sheng Wu Xue Bao; 1995 Sep; 28(3):241-6. PubMed ID: 8571707
[TBL] [Abstract][Full Text] [Related]
7. A nonantisense sequence-selective effect of a phosphorothioate oligodeoxynucleotide directed against the epidermal growth factor receptor in A431 cells.
Coulson JM; Poyner DR; Chantry A; Irwin WJ; Akhtar S
Mol Pharmacol; 1996 Aug; 50(2):314-25. PubMed ID: 8700139
[TBL] [Abstract][Full Text] [Related]
8. 2'-O-methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in vitro.
Yoo BH; Bochkareva E; Bochkarev A; Mou TC; Gray DM
Nucleic Acids Res; 2004; 32(6):2008-16. PubMed ID: 15064360
[TBL] [Abstract][Full Text] [Related]
9. Gene silencing nucleic acids designed by scanning arrays: anti-EGFR activity of siRNA, ribozyme and DNA enzymes targeting a single hybridization-accessible region using the same delivery system.
Beale G; Hollins AJ; Benboubetra M; Sohail M; Fox SP; Benter I; Akhtar S
J Drug Target; 2003 Aug; 11(7):449-56. PubMed ID: 15203934
[TBL] [Abstract][Full Text] [Related]
10. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence.
Ziegler A; Luedke GH; Fabbro D; Altmann KH; Stahel RA; Zangemeister-Wittke U
J Natl Cancer Inst; 1997 Jul; 89(14):1027-36. PubMed ID: 9230884
[TBL] [Abstract][Full Text] [Related]
11. Antisense phosphorothioate oligodeoxynucleotide down-regulation of the insulin-like growth factor I receptor in ovarian cancer cells.
Müller M; Dietel M; Turzynski A; Wiechen K
Int J Cancer; 1998 Aug; 77(4):567-71. PubMed ID: 9679760
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotides to the epidermal growth factor receptor.
Witters L; Kumar R; Mandal M; Bennett CF; Miraglia L; Lipton A
Breast Cancer Res Treat; 1999 Jan; 53(1):41-50. PubMed ID: 10206071
[TBL] [Abstract][Full Text] [Related]
13. Antisense imaging of epidermal growth factor-induced p21(WAF-1/CIP-1) gene expression in MDA-MB-468 human breast cancer xenografts.
Wang J; Chen P; Mrkobrada M; Hu M; Vallis KA; Reilly RM
Eur J Nucl Med Mol Imaging; 2003 Sep; 30(9):1273-80. PubMed ID: 12640557
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect of EGFR antisense oligodeoxynucleotide on human hepatoma cell line.
Gong ZB; Liu JM; Li YM
Hepatobiliary Pancreat Dis Int; 2005 Aug; 4(3):433-6. PubMed ID: 16109531
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of generation 2 and 3 poly(propylenimine) dendrimers for the potential cellular delivery of antisense oligonucleotides targeting the epidermal growth factor receptor.
Hollins AJ; Benboubetra M; Omidi Y; Zinselmeyer BH; Schatzlein AG; Uchegbu IF; Akhtar S
Pharm Res; 2004 Mar; 21(3):458-66. PubMed ID: 15070097
[TBL] [Abstract][Full Text] [Related]
16. Reduction of erbB2 gene product in mamma carcinoma cell lines by erbB2 mRNA-specific and tyrosine kinase consensus phosphorothioate antisense oligonucleotides.
Bertram J; Killian M; Brysch W; Schlingensiepen KH; Kneba M
Biochem Biophys Res Commun; 1994 Apr; 200(1):661-7. PubMed ID: 7909438
[TBL] [Abstract][Full Text] [Related]
17. Modulation of multidrug resistance in human leukemia cells with mdr1-targeted antisense oligonucleotides using variable treatment schedules.
Dassow H; Lassner D; Remke H; Preiss R
Int J Clin Pharmacol Ther; 2000 Apr; 38(4):209-16. PubMed ID: 10783831
[TBL] [Abstract][Full Text] [Related]
18. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
[TBL] [Abstract][Full Text] [Related]
19. Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines.
Ciardiello F; Caputo R; Troiani T; Borriello G; Kandimalla ER; Agrawal S; Mendelsohn J; Bianco AR; Tortora G
Int J Cancer; 2001 Jul; 93(2):172-8. PubMed ID: 11410862
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.
Salatino M; Schillaci R; Proietti CJ; Carnevale R; Frahm I; Molinolo AA; Iribarren A; Charreau EH; Elizalde PV
Oncogene; 2004 Jul; 23(30):5161-74. PubMed ID: 15122317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
